Originally published In Press as doi:10.1074/jbc.M505220200 on August 26, 2005
J. Biol. Chem., Vol. 280, Issue 43, 35967-35973, October 28, 2005
Calcium/Calmodulin Regulates Ubiquitination of the Ubiquitin-specific Protease TRE17/USP6*
Chuanlu Shen
12,
Ying Ye
2,
Sarah E. Robertson
,
Alan W. Lau
,
Don-On D. Mak¶, and
Margaret M. Chou
3
From the
Departments of
Cell and Developmental Biology,
Pharmacology, and ¶Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6160
The TRE17 (USP6/TRE-2) oncogene induces tumorigenesis in both humans and mice. However, little is known regarding its regulation or mechanism of transformation. TRE17 encodes a TBC (Tre-2/Bub2/Cdc16)/Rab GTPase-activating protein homology domain at its N terminus and a ubiquitin-specific protease at its C terminus. In the current study, we identified the ubiquitous calcium (Ca2+)-binding protein calmodulin (CaM) as a novel binding partner for TRE17. CaM bound directly to TRE17 in a Ca2+-dependent manner both in vitro and in vivo. The CaM-binding site was mapped to two hydrophobic motifs near the C terminus of the TBC domain. Point mutations within these motifs significantly reduced the interaction of TRE17 with CaM. We further found that TRE17 is monoubiquitinated and promotes its own deubiquitination in vivo. CaM binding-deficient mutants of TRE17 exhibited significantly reduced monoubiquitination, suggesting that binding of Ca2+/CaM to TRE17 promotes this modification. Consistent with this notion, treatment of cells with the CaM inhibitor W7 reduced levels of TRE17 monoubiquitination. Interestingly, the calcium ionophore A23187 induced accumulation of a polyubiquitinated TRE17 species. The effect of A23187 was attenuated in CaM binding-deficient mutants of TRE17. Taken together, these studies indicate a role for Ca2+/CaM in regulating ubiquitination through direct interaction with TRE17.
Received for publication, May 11, 2005
, and in revised form, August 15, 2005.
* This work was supported by Public Health Service Grant CA-81415 from NCI, National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at http://www.jbc.org) contains supplemental material.
1 Current address: Dept. of Pathophysiology, Southeast University Medical College, Nanjing, China.
2 These authors contributed equally to this work.
3 To whom correspondence should be addressed: Dept. of Cell and Developmental Biology, University of Pennsylvania School of Medicine, BRBII, Rm. 1011, 421 Curie Blvd., Philadelphia, PA 19104-6160. Tel.: 215-573-4126; Fax: 215-898-9871; E-mail: mmc{at}mail.med.upenn.edu.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. K. Meray and P. T. Lansbury Jr.
Reversible Monoubiquitination Regulates the Parkinson Disease-associated Ubiquitin Hydrolase UCH-L1
J. Biol. Chem.,
April 6, 2007;
282(14):
10567 - 10575.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.